| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 156.41M | 156.41M | 136.62M | 116.44M | 99.08M | 98.52M |
| Gross Profit | 48.43M | 47.36M | 44.04M | 36.86M | 32.59M | 28.38M |
| EBITDA | 15.70M | 15.75M | 12.54M | 13.20M | 12.02M | 11.03M |
| Net Income | 6.56M | 6.56M | 3.66M | 5.19M | 6.48M | 3.99M |
Balance Sheet | ||||||
| Total Assets | 192.76M | 192.76M | 186.34M | 155.41M | 154.69M | 142.61M |
| Cash, Cash Equivalents and Short-Term Investments | 8.56M | 8.56M | 12.12M | 17.72M | 24.29M | 30.08M |
| Total Debt | 25.47M | 25.47M | 23.96M | 8.58M | 10.96M | 9.80M |
| Total Liabilities | 77.53M | 77.53M | 73.33M | 46.96M | 48.88M | 43.65M |
| Stockholders Equity | 113.14M | 113.14M | 110.44M | 106.04M | 103.82M | 97.30M |
Cash Flow | ||||||
| Free Cash Flow | 8.74M | 8.80M | -11.06M | 985.00K | -1.10M | 4.03M |
| Operating Cash Flow | 11.56M | 11.61M | 1.33M | 9.68M | 3.88M | 6.45M |
| Investing Cash Flow | -14.29M | -14.29M | -13.58M | -12.52M | -9.35M | 24.56M |
| Financing Cash Flow | -436.00K | -436.00K | 6.78M | -3.40M | -371.00K | -5.85M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £179.73M | 27.37 | 5.87% | 1.02% | 14.49% | 76.33% | |
69 Neutral | £1.32B | 48.27 | 4.10% | 3.30% | -6.95% | -52.08% | |
67 Neutral | £653.37M | 23.89 | 8.04% | 4.87% | -7.30% | -59.71% | |
65 Neutral | £116.08M | 24.05 | 3.82% | 6.69% | -13.30% | -60.03% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
61 Neutral | £101.50M | -8.12 | -17.46% | ― | 21.17% | -237.25% | |
46 Neutral | £414.26M | -9.10 | -18.47% | ― | 57.73% | -67.12% |
Avingtrans plc has granted options over 293,000 ordinary shares to non-PDMR employees under its Share Option Plan, with an exercise price of 515.0 pence per share, as part of its long-term incentive arrangements. The options will vest after three years and are contingent on the company’s adjusted earnings per share at least matching the increase in the Retail Prices Index over the vesting period, aligning employee rewards with both company performance and inflation-protected shareholder value.
The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.
Avingtrans has appointed experienced MedTech executive Stuart Gall as Chief Executive Officer of its medical and industrial imaging division, effective 1 January 2026, tasking him with driving the strategic development and commercialisation of portfolio businesses Adaptix, Magnetica and Scientific Magnets. Gall’s track record in scaling medical technology companies from university spin-outs to globally partnered, publicly listed businesses is expected to accelerate market adoption of Avingtrans’ disruptive imaging technologies and support the Group’s efforts to enhance the value of this division for shareholders and strengthen its positioning in high-growth medical and industrial imaging markets.
The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.
Avingtrans plc announced the successful passage of all resolutions at its Annual General Meeting, including the appointment of Austen Adams as Group Chief Operating Officer. This appointment aligns with the company’s strong performance and market expectations, potentially enhancing its operational capabilities and industry positioning.
The most recent analyst rating on (GB:AVG) stock is a Hold with a £538.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.
Avingtrans PLC announced the exercise of 591,614 options over ordinary shares by CEO Steve McQuillan and CFO Stephen King as part of the Company’s Executive Shared Ownership Plans. This transaction will not result in the issuance of new shares, maintaining the total number of shares with voting rights at 33,130,422. The exercise of these options reflects the company’s internal management strategies and may have implications for shareholder calculations under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:AVG) stock is a Hold with a £538.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.
Avingtrans plc announced that its subsidiary, Adaptix Limited, has received FDA 510(k) clearance for its Adaptix Ortho350, a 3D imaging system for orthopaedic use. This clearance allows Adaptix to enter the U.S. healthcare market, marking a significant milestone in its mission to transform radiology. The Ortho350 offers low-dose, high-quality imaging at the point-of-care, enhancing diagnostic accuracy and patient outcomes. This achievement is expected to open new opportunities in the substantial U.S. orthopaedic imaging market, validating the commercial potential of Adaptix’s technology.
The most recent analyst rating on (GB:AVG) stock is a Hold with a £538.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.